首页> 外文期刊>British Journal of Cancer >Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer
【24h】

Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer

机译:雄激素受体和雄激素应答蛋白载脂蛋白D在人类乳腺癌中的表达

获取原文
获取外文期刊封面目录资料

摘要

Little is known regarding the activity and function of the androgen receptor (AR) in human breast cancer. In the present study AR was evaluated in untreated primary breast cancers using antisera to the amino- and carboxy-termini of the receptor and quantitated using colour video image analysis. A strong correlation between tissue concentration and percentage AR-positive cells was observed for each antiserum. However, comparison of percentage positive cells using the amino- and carboxy-terminal AR antisera in individual breast cancer specimens revealed a subset of tumours with discordantly increased staining for the carboxy terminus. These findings suggest the presence of amino-terminal-truncated AR in a proportion of breast cancer cells or presence of AR mutations or associated protein alterations that affect binding of the amino-terminal AR antiserum. Immunohistochemical expression of the androgen-regulated glycoprotein, apolipoprotein D (apo-D), was also evaluated in the breast cancer specimens. Focal positivity of apo-D staining, which did not always co-localise with AR-positive cells, was observed within breast tumours. Furthermore, no correlation was evident between percentage positive cells stained for AR and apo-D in breast cancer specimens. These findings indicate that, although apo-D expression is androgen regulated in human breast cancer cell lines in vitro, its expression in primary breast cancers may be regulated by other factors. The expression of AR in primary breast cancers also suggests that the receptor may be involved in tumour responsiveness or in abnormal responses to endocrine therapies.
机译:关于人类乳腺癌中雄激素受体(AR)的活性和功能知之甚少。在本研究中,在未治疗的原发性乳腺癌中使用受体氨基和羧基末端的抗血清评估了AR,并使用彩色视频图像分析对其进行了定量。对于每种抗血清,观察到组织浓度与AR阳性细胞百分比之间存在很强的相关性。然而,在单个乳腺癌样本中使用氨基末端和羧基末端AR抗血清对阳性细胞百分比的比较显示,一部分羧基末端的染色异常增加。这些发现表明一定比例的乳腺癌细胞中存在氨基末端截短的AR,或者存在影响氨基末端AR抗血清结合的AR突变或相关蛋白改变。还评估了乳腺癌标本中雄激素调节糖蛋白载脂蛋白D(apo-D)的免疫组织化学表达。在乳腺肿瘤中观察到apo-D染色的局灶性阳性,并不总是与AR阳性细胞共定位。此外,乳腺癌样本中AR和apo-D染色的阳性细胞百分比之间没有明显的相关性。这些发现表明,尽管载脂蛋白D的表达在体外在人乳腺癌细胞系中受雄激素调节,但其在原发性乳腺癌中的表达可能受到其他因素的调节。 AR在原发性乳腺癌中的表达还表明该受体可能与肿瘤反应性或对内分泌疗法的异常反应有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号